Metasyn joins forces with Daiichi
Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in
Contrast developer Metasyn has signed a $12 million agreement
with Daiichi Radioisotope Laboratories of Tokyo for Japanese development
and marketing of MS-325, Metasyn's vascular MRI contrast agent.
Under the agreement, Metasyn will receive $12 million in license
fees, milestone payments, and an equity investment, in addition
to royalties on sales of the product. Daiichi will be responsible
for clinical development, registration, and commercialization
of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture
MS-325 for Daiichi and will retain rights to the product outside
Japan. Metasyn expects to begin clinical trials of the agent in
the U.S. this year.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
